World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 14 March 2016
Main ID:  EUCTR2013-002660-17-PT
Date of registration: 14/11/2014
Prospective Registration: Yes
Primary sponsor: Novartis Pharma Services AG
Public title: Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis
Scientific title: Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis - ACROSS
Date of first enrolment: 02/01/2015
Target sample size: 281
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002660-17
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no  
Phase: 
Countries of recruitment
Canada Denmark Finland France Germany Italy Poland Portugal
Spain Switzerland United Kingdom
Contacts
Name: Clinical Trial Information Desk   
Address:  Forum 1, Novartis Campus 4056 Basel Switzerland
Telephone: +41613241111
Email: clinicaltrial.enquires@novartis.com
Affiliation:  Novartis Pharma Service AG
Name: Clinical Trial Information Desk   
Address:  Forum 1, Novartis Campus 4056 Basel Switzerland
Telephone: +41613241111
Email: clinicaltrial.enquires@novartis.com
Affiliation:  Novartis Pharma Service AG
Key inclusion & exclusion criteria
Inclusion criteria:
1. Written informed consent must be obtained before any assessment is performed
2. Randomized in study FTY720D2201 and received at least one dose of study drug
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 266
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15

Exclusion criteria:
Patients not meeting the inclusion criteria are excluded.



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
multiple sclerosis
MedDRA version: 18.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Intervention(s)

Trade Name: Gilenya
Product Name: Fingolmod
Product Code: FTY720D
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Fingolimod
CAS Number: 162359-56-0
Current Sponsor code: FTY720D
Other descriptive name: FINGOLIMOD HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-

Primary Outcome(s)
Main Objective: To investigate whether continuous use of fingolimod over 10 years reduces the progression of disability, as measured by the mean Expanded Disability Status Scale (EDSS) score, compared to shorter treatment duration
Primary end point(s): the change from baseline (D2201 baseline) in EDSS score at the 10-year follow-up visit
Secondary Objective: 1. Additional assessments of the development of disability from disease onset and from start of treatment in D2201
2. Assessment of change in MRI measures
3. Assessment of novel MRI measures at 10 years
4. Correlational analyses – duration of treatment with clinical outcomes, MRI measures with clinical outcomes, cognitive measures with MRI outcomes. Atrophy measures comparing results with old MRI scanner and new MRI scanner at
10 years (for sites with access to the D2201/2201E1 MRI scanner)
Timepoint(s) of evaluation of this end point: 10 year since starting study (FTY720D2201)
Secondary Outcome(s)
Secondary end point(s): Proportion of patients with disability progression at 10 years will be summarized
-Change in MRI measures at 10 year follow up
-New MRI measures (deep gey matter volume, corical thickness, T1 hypointense lesion “black hole” volume) will be
measured at 10 year follow up
-Correlative analysis (treatment duration and clinical outcomes; MRI measures and clinical outcomes; cognitive measures and MRI outcomes; atrophy measures between old and new MRI scans) will be done at 10 year follow up
Timepoint(s) of evaluation of this end point: 10 year since starting study (FTY720D2201)
Secondary ID(s)
2013-002660-17-IT
CFTY720D2201E2
Source(s) of Monetary Support
Novartis Pharma Services AG
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history